top of page

PREGNANCY & ADDICTION

01/

The American College of Obstetrics & Gynecology reiterated their official statement in 2017 that buprenorphine is the recommendation for treatment of addiction in pregnancy.

04/

Guidelines and recommendations from the Substance Abuse and Mental Health Services Administration regarding addiction treatment in pregnancy.

07/

The genetic polymorphisms of OPRM1 and COMT were associated with decreased hospital stays in infants diagnosed with NAS.

10/

The official Finnegan Neonatal Abstinence Scoring Tool used universally in NICUs.

13/

A meta-analysis showing no association between methadone dose and NAS severity.

16/

A retrospective study from 2000-2009 about the overall cost of NAS in the US. Average cost of stay in 2009 was $53,400, and 77.6% of stays were billed to Medicaid.

19/

Official guidelines from the Substance Abuse and Mental Health Services Administration regarding buprenorphine as the recommended treatment in OUD and to not taper pregnant patients.

22/

The specific needs of women who suffer from substance abuse are addressed in this comprehensive overview with specific guidelines from the Substance Abuse and Mental Health Services Administration.

03/

An interesting study of attempting to force taper and detox patients during pregnancy that showed a significant increase in NAS rates. This study contributed to the ACOGs further recommendations for continued treatment with buprenorphine in pregnancy for addiction.

06/

A large review of literature from the past 50 years about the higher rates of relapse and no improvement of newborn health in pregnant women who have gone through detoxification.

09/

High Point Clinic's Dr. Vance Shaw, MD reviews NAS.

12/

A review of over 1,600 articles from the American Society of Addiction Medicine in 2017 about treating addiction in pregnancy.

15/

Concomitant use of methadone with benzodiazepines increases rates of NAS and length of hospital stay.

18/

High Point Clinic's Dr. Vance Shaw, MD offers evidence-based guidelines on treating pregnant patients with OUD.

21/

In a large review of research comparing buprenorphine and methadone in pregnancy, buprenorphine was shown to be superior in both maternal and fetal outcomes.

24/

A powerpoint presentation on effective Finnegan scoring and how to assure accurate scoring across providers.

02/

A powerful study from the New England Journal of Medicine that showed superiority of buprenorphine over methadone in pregnancy with decreased rates of NAS and shorter hospital stays.

05/

Detoxification is possible during pregnancy, but requires significant resources and is not the recommendation by all official organizations.

08/

A look at if there is an association between opioid detoxification during pregnancy and fetal distress or death as well as maternal relapse.

11/

Recommendations from the CDC that breastfeeding is safe in patients with HCV and/or HBV. There is insufficient data to conclude recommendations on safety in cracked or bleeding nipples.

14/

In a meta-analysis, buprenorphine shows to be superior to methadone in pregnancy.

17/

An overview with recommendations from the American Academy of Pediatrics on neonatal drug withdrawal.

20/

An extensive review with recommendations on all aspects of treating OUD in pregnancy from the Substance Abuse and Mental Health Services Administration.

23/

A brief overview of OUD and treatment options for pregnant patients.

bottom of page